Curis, Inc. (NASDAQ:CRIS) Given Consensus Rating of “Hold” by Brokerages

Curis, Inc. (NASDAQ:CRIS – Get Rating) has been given an average rating of “Hold” by the seven research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $12.25.

Several analysts have issued reports on the company. StockNews.com assumed coverage on Curis in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Cantor Fitzgerald dropped their price objective on Curis from $12.00 to $4.00 in a research note on Tuesday, April 5th. B. Riley decreased their target price on Curis from $22.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, April 5th. Raymond James downgraded Curis from an “outperform” rating to a “market perform” rating and set a $15.00 target price on the stock. in a research report on Monday, April 4th. Finally, Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a research report on Tuesday, March 1st.

NASDAQ:CRIS traded down $0.07 on Friday, hitting $1.31. The company’s stock had a trading volume of 963,820 shares, compared to its average volume of 3,900,982. The stock has a fifty day moving average of $2.66 and a two-hundred day moving average of $4.35. The firm has a market capitalization of $120.05 million, a P/E ratio of -2.62 and a beta of 2.87. Curis has a one year low of $1.28 and a one year high of $17.40.

Curis (NASDAQ:CRIS – Get Rating) last released its quarterly earnings data on Thursday, February 24th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $3.14 million during the quarter, compared to the consensus estimate of $3.04 million. Curis had a negative net margin of 426.67% and a negative return on equity of 42.46%. During the same quarter in the prior year, the company earned ($0.11) EPS. On average, equities research analysts anticipate that Curis will post -0.63 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of CRIS. Cutler Group LP grew its position in Curis by 46.3% during the fourth quarter. Cutler Group LP now owns 9,800 shares of the biotechnology company’s stock worth $46,000 after buying an additional 3,100 shares in the last quarter. Virtu Financial LLC acquired a new stake in Curis during the fourth quarter worth approximately $49,000. Total Clarity Wealth Management Inc. acquired a new stake in Curis during the third quarter worth approximately $50,000. Advisor Group Holdings Inc. grew its position in Curis by 36.1% during the third quarter. Advisor Group Holdings Inc. now owns 7,540 shares of the biotechnology company’s stock worth $58,000 after buying an additional 2,000 shares in the last quarter. Finally, Royal Bank of Canada grew its position in Curis by 198.5% during the second quarter. Royal Bank of Canada now owns 8,357 shares of the biotechnology company’s stock worth $67,000 after buying an additional 5,557 shares in the last quarter. 80.93% of the stock is currently owned by institutional investors.

Curis Company Profile (Get Rating)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

See Also